Genetic analysis of white patients with thrombotic microangiopathy and white control subjects
| . | Control subjects . | TM patients with normal VWCP . | TM patients with deficient VWCP . | |||||
|---|---|---|---|---|---|---|---|---|
| n . | % abnormal (heterozygous/ homozygous) . | n . | % abnormal (heterozygous/ homozygous) . | P* . | n . | % abnormal (heterozygous/ homozygous) . | P† . | |
| Factor V G1691A | 186 | 3 (6/0) | 11 | 36 (3/1) | < .001 | 16 | 0 (0/0) | > .99 |
| Factor II G20210A | 186 | 3 (5/0) | 11 | 0 (0/0) | > .99 | 16 | 6 (1/0) | .394 |
| MTHFR C677T | 186 | 11‡ (20) | 11 | 0‡ (0) | .607 | 16 | 0‡ (0) | .377 |
| GP1a C807T | 280 | 60 (133/34) | 11 | 73 (7/1) | .535 | 16 | 50 (7/1) | .4452-153 |
| PAI-1 4G/5G | 173 | 29‡ (51) | 11 | 27‡ (3) | > .99 | 15 | 27‡ (4) | > .99 |
| . | Control subjects . | TM patients with normal VWCP . | TM patients with deficient VWCP . | |||||
|---|---|---|---|---|---|---|---|---|
| n . | % abnormal (heterozygous/ homozygous) . | n . | % abnormal (heterozygous/ homozygous) . | P* . | n . | % abnormal (heterozygous/ homozygous) . | P† . | |
| Factor V G1691A | 186 | 3 (6/0) | 11 | 36 (3/1) | < .001 | 16 | 0 (0/0) | > .99 |
| Factor II G20210A | 186 | 3 (5/0) | 11 | 0 (0/0) | > .99 | 16 | 6 (1/0) | .394 |
| MTHFR C677T | 186 | 11‡ (20) | 11 | 0‡ (0) | .607 | 16 | 0‡ (0) | .377 |
| GP1a C807T | 280 | 60 (133/34) | 11 | 73 (7/1) | .535 | 16 | 50 (7/1) | .4452-153 |
| PAI-1 4G/5G | 173 | 29‡ (51) | 11 | 27‡ (3) | > .99 | 15 | 27‡ (4) | > .99 |
TM indicates thrombotic microangiopathy; VWCP, von Willebrand factor–cleaving protease; MTHFR, methylenetetrahydrofolate reductase; PAI-1, type 1 plasminogen activator inhibitor.
Comparison between control subjects and TM patients with normal VWCP.
Comparison between control subjects and TM patients with deficient VWCP.
For MTHFR C677T and PAI-1 4G/5G, the abnormal is homozygous only, heterozygous individuals are classified as normal.
P value is from χ2; all otherP values are from Fisher exact test.